TELIX PHARMACEUTICALS LIMITED (TLX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

TLX

TLX - TELIX PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 11.42
Index: ASX100 | ASX200 | ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$9.76

02 Mar
2026

-0.240

OPEN

$9.65

-2.40%

HIGH

$9.86

1,999,028

LOW

$9.56

TARGET
$24.55 151.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
TLX: 1
Title FY26
Forecast		 FY27
Forecast
EPS (cps) - 11.4 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-3.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx1,246.6 M
Book Value Per Share xxxxxxxxxxxxxxx183.9
Net Operating Cash Flow xxxxxxxxxxxxxxx-26.8 M
Net Profit Margin xxxxxxxxxxxxxxx-0.89 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-1.86 %
Return on Invested Capital xxxxxxxxxxxxxxx-0.91 %
Return on Assets xxxxxxxxxxxxxxx-0.67 %
Return on Equity xxxxxxxxxxxxxxx-1.86 %
Return on Total Capital xxxxxxxxxxxxxxx2.23 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-85.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx28 M
Long Term Debt xxxxxxxxxxxxxxx672 M
Total Debt xxxxxxxxxxxxxxx700 M
Goodwill - Gross xxxxxxxxxxxxxxx298 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx213 M
Price To Book Value xxxxxxxxxxxxxxx6.09

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx86.8 M
Capex % of Sales xxxxxxxxxxxxxxx6.97 %
Cost of Goods Sold xxxxxxxxxxxxxxx584 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx635 M
Research & Development xxxxxxxxxxxxxxx266 M
Investments - Total xxxxxxxxxxxxxxx56 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

5
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

27/02/2026

1

Buy

-

-

UBS keeps a Buy rating and US$20.00 target for Telix Pharmaceuticals following FY25 results.

The broker believes value creation catalysts in 2026 could shift sentiment. The analysts' forecasts incorporate stronger Prostate-Specific Membrane Antigen (PSMA) growth assumptions.

A  summary of the broker's initial take on FY25 results follows.

At first look, Telix Pharmaceuticals reported 2025 revenue of US$783m, up 56% y/y and 3% ahead of UBS, with EBITDA of US$196m beating by 6%, reflecting strong Illuccix momentum across the US and initial international roll-out.

UBS highlights FY26 revenue guidance of US$1.18-US1.23bn, implying growth of around 51% at the midpoint, driven by continued PSMA PET expansion and manufacturing scale-up.

The broker points to near-term catalysts including US approval and launch timing for Gozellix, European regulatory progress, and advancing pivotal studies across kidney cancer and glioblastoma programs. 

FORECAST
UBS forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.52 cents.
UBS forecasts a full year FY27 dividend of 0.00 cents and EPS of 25.92 cents.

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

27/01/2026

1

Buy

$28.50

192.01%

Canaccord Genuity comments Telix Pharmaceuticals reported a solid 4Q2025result, noting early evidence its two-product PSMA strategy is working, supported by improving volumes and pricing following the introduction of Gozellix.

The broker highlights 4Q25 revenue of US$208m was slightly below its forecast but ahead of consensus, with Telix benefiting from temporary pass-through payment status as the only PSMA agent in hospital outpatient settings for the next three quarters.

Canaccord retained its Buy rating and $28.50 target price, citing multiple upcoming clinical and regulatory catalysts in 2026 that could support a valuation re-rating 
Access Extra Coverage Research History >

TLX STOCK CHART

FNArena News on TLX

1
Rudi’s View: Positives From February Results

Feb 26 2026 - Rudi's View
2
FNArena Corporate Results Monitor – 23-02-2026

Feb 23 2026 - Australia
3
Rudi’s View: Woolies, CSL, Macquarie (& More)

Feb 05 2026 - Rudi's View
4
Why Gold Beats Bitcoin & ASX Opportunities

Feb 04 2026 - Commodities
5
Rudi’s View: Many February Uncertainties

Feb 04 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
2
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
3
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
4
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
5
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
6
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
7
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
8
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
9
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
10
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View